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Aim The neural cardiac therapy for heart failure (NECTAR-HF) was a randomized sham-controlled trial designed to evaluate
whether a single dose of vagal nerve stimulation (VNS) would attenuate cardiac remodelling, improve cardiac function
and increase exercise capacity in symptomatic heart failure patients with severe left ventricular (LV) systolic dysfunction
despite guideline recommended medical therapy.
Methods Patientswererandomizedina2 : 1ratiotoreceivetherapy(VNSON)orcontrol(VNSOFF) fora6-monthperiod.Theprimary
endpoint was thechange in LVend systolic diameter (LVESD) at 6 months for control vs. therapy, with secondaryendpoints of
otherechocardiographymeasurements, exercisecapacity, quality-of-life assessments, 24-hHolter, andcirculatingbiomarkers.
Results Of the 96 implanted patients, 87 had paired datasets for the primary endpoint. Change in LVESD from baseline to
6 months was 20.04+0.25 cm in the therapy group compared with 20.08+ 0.32 cm in the control group
(P ¼ 0.60). Additional echocardiographic parameters of LV end diastolic dimension, LV end systolic volume, left ventricu-
lar end diastolic volume, LV ejection fraction, peak V02, and N-terminal pro-hormone brain natriuretic peptide failed to
show superiority compared to the control group. However, there were statistically significant improvements in quality of
life for the Minnesota Living with Heart Failure Questionnaire (P ¼ 0.049), New York Heart Association class
(P ¼ 0.032), and the SF-36 Physical Component (P ¼ 0.016) in the therapy group.
Conclusion Vagal nerve stimulation as delivered in the NECTAR-HF trial failed to demonstrate a significant effect on primary and sec-
ondary endpoint measures of cardiac remodelling and functional capacity in symptomatic heart failure patients, but
quality-of-life measures showed significant improvement.
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Increased sympathetic activation and reduced parasympathetic tone,
as reflected by reduced baroreflex sensitivity and/or decreased heart
rate variability, are potentially important pathophysiological contri-
butors to the progression of heart failure (HF) irrespective of aeti-
ology, and are associated with poor outcome.1,2 Experimental
augmentation of parasympathetic tone has recently emerged as a po-
tential therapeutic approach to normalizing autonomic imbalance
and inhibiting the progression of HF.3,4 The effect of enhancing para-
sympathetic tone via direct vagal nerve stimulation (VNS) was re-
cently assessed in a non-randomized observational study of 32 HF
patients with left ventricular (LV) systolic dysfunction, with results
suggesting that vagal stimulation favourably influenced quality of
life, exercise capacity, and LV remodelling.5,6
The neural cardiac therapy for heart failure (NECTAR-HF) trial
(www.clinicaltrials.gov, NCT01385176) is the first randomized sham-
controlled trial designed to evaluate whether right cervical VNS is
safe and might attenuate cardiac remodelling, improve cardiac function,
increase exercise capacity, enhance quality of life, and favourably impact
circulating biomarkers in symptomatic HF patients with severe LV sys-
tolic dysfunction receiving guideline recommended medical therapy.7
Methods
The NECTAR-HF study design has been published previously.8 The com-
plete protocol can be viewed in the Supplementary materials online that
accompany this manuscript. Twenty-seven centres across Western
Europe were approved for participation in the study by the appropriate
ethics committees and regulatory agencies. The study was conducted in
accordance with the Declaration of Helsinki, ISO 14155: 2011 and all
other applicable regulations as determined by the country of submission.
Participants provided written informed consent prior to enrolment.
Patient eligibility criteria
Patients were required to have a documented LV ejection fraction (LVEF)
of ≤ 35%, an LV end diastolic dimension (LVEDD) of ≥55 mm, and a
New York Heart Association (NYHA) classification of II or III. Patients
also had to be treated with medical therapy per European heart failure
guidelines7 for at least 30 days prior to enrolment. Key exclusion criteria
included persistent or permanent atrial fibrillation, cardiac resynchroni-
zation (CRT) for ,1 year or a QRS of .130 ms without CRT, type I dia-
betes, type II diabetes for .5 years, sleep disordered breathing that had
been treated for ,6 months, a surgically correctable cause of HF, recent
HF hospitalization, or myocardial infarction (30 or 90 days, respectively),
or an indication for dialysis.
Therapy
In all patients, implantation of the VNS system was performed within 45
days of the pre-implant screening period. Figure 1 shows the implanted
system. A self-sizing bipolar helical lead was implanted around the right
vagus nerve in the cervical region and the lead body was tunnelled over
the clavicle. The terminal end was connected to the pulse generator
that was implanted in a subcutaneous pectoral pocket. During the
implant procedure, the NECTAR-HF system was tested for system integ-
rity and to verify effective stimulation. Prior to discharge from the hos-
pital, patients were instructed to charge their implanted device once a
week for an hour by placing the wireless external charger over the gen-
erator. Patients returned to the clinic 14+ 5 days after the implant for
baseline assessment. At the completion of baseline testing, patients
were randomized in a 2 : 1 block permuted manner to either therapy
or control.
During therapy titration, the stimulation amplitude was increased until
patients either experienced side effects that were unpleasant (e.g. neck
pain or coughing), or the maximum allowed current for chronic stimula-
tion was reached (4 mA). The recommended settings were 20 Hz, with
10 s on, 50 s off, and a pulse width of 300 ms. So as to maintain blinding,
regardless of group randomization, all patients underwent therapy titra-
tion until first detectable level of stimulation, such as a tickling sensation in
the throat, coughing, or voice alteration, but in the control group stimu-
lation was turned off at the end of the visit.
Following the baseline visit, all patients returned for three stimulation
titrations within the next 30 days. After the final titration, the 6-month
time window began. Therapy patients received active stimulation;
control patients’ devices remained off. Additional follow-up visits
were performed at 3 and 6 months for device checks, adverse event
reporting, and/or endpoint assessments. Patients who had a defibrilla-
tor underwent routine device checks to assess for possible system
interference.
Blinding
Programming of the generator was performed by a physician un-blinded
to treatment assignment, while all other investigators and site study staff
involved in endpoint data collection were blinded to randomization.
Before and after titrations, a standard statement was read to patients
informing them that they may feel sensations during titrations, or on a
chronic basis, but that these sensations were not indicative that they
were receiving therapeutic stimulation. At scheduled visits, patients
were queried on whether they believed they were assigned to the
therapy or control group. To assess the degree to which patients
were blinded to treatment assignment, a blinding index analysis was
performed. A detailed description of the analysis has been described
elsewhere.9
At the end of 6 months, all patients in the control group had their
devices turned ON to receive active therapy. Additional follow-up
visits occur every 3 months through 18 month. Because NECTAR-HF
is an on-going trial, the present report is limited to the results of the 6
month randomized and controlled phase.
Endpoints and sample size
The change in left ventricular end systolic diameter (LVESD) from base-
line (randomization visit) to 6 months was selected as primary efficacy
endpoint. Echocardiography exams were performed by treatment-
blinded sonographers who were certified by the echocardiography
core lab (Brigham and Women’s Hospital, Boston, MA, USA). Details
of the echocardiography views and analysis can be found in the Supple-
mentary materials online.
Secondary endpoints included LV end systolic volume (LVESV), LVEF,
peak VO2, N-terminal pro-hormone brain natriuretic peptide
(NT-proBNP), Holter derived indices of autonomic nerve modulation
(standard deviation of normal to normal beats, SDNN; standard devi-
ation of the average normal to normal beats, SDANN; root mean
square of successive differences, RMSSD), Minnesota Living with Heart
Failure Questionnaire & (MLHFQ),9 the Short Form 36 Health Survey
(SF-36)10 and NYHA functional class. All procedures for echocardiog-
raphy, cardiopulmonary exercise testing, quality-of-life and plasma
collection are described in the main design paper.8 NT-proBNP
(Roche Elecsys ECLIA) was quantified at the Clinical Reference Labora-
tory (Lenexa, KS, USA) and the 45-biomarker Human Inflammation-
MAPw v. 1.0 (multiplexed immunoassay) was performed at Myriad
RBM (Austin, TX, USA).
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The primary endpoint of LVESD was analysed using a modified intention
to treat analysis on the final dataset, where only patients with paired
datasets from baseline and 6 months were included in the analysis.
Sample size calculation and the statistical analysis plan have been
described elsewhere (Supplementary materials online),8 but was esti-
mated that the 96 patients study was powered to detect a 5+ 6 mm dif-
ference in LVESD between groups using a 2 : 1 randomization, assuming
40% data attrition.
An as-treated sub-analysis was performed including only patients who
received per-protocol therapy for at least 85% of the randomization
period. The primary endpoint of LVESD was tested using a general
linear model, with LVESD as the outcome and randomization group,
and baseline LVESD as acovariate in the model. Statistical testingwasper-
formed at a significance level of 5%.
Testing of all secondary outcomes, except NYHA, was performed
using the same methodology that was used for the primary endpoint.
NYHA was assessed using a Cochran-Armitage test for trend, in which
the number of NYHA classes changed from baseline to 6 months was
compared between the randomization groups. Exploratory analyses
were performed on pre-specified endpoints and subgroups as defined
in the Statistical Analysis Plan (see Supplementary materials online).
All-cause mortality will be further formally evaluated as the primary
safety endpoint at 18 months as specified in the protocol.
Results
Of the 118 patients enrolled, 96 were found to be eligible and were
implantedacross24centres (7 siteswith5–10 implants, 1 sitewith13
implants). As shown in Figure 2, 87 patients completed the 6-month
study having paired echocardiography exams. In addition, 86 patients
had paired blood samples, and 83 had paired exercise tests available.
Patient characteristics
Table 1 summarizes the patient characteristics. Body mass index was
significantly greater and diuretic usage higher in the control group,
while statin usage was statistically higher in the therapy group. No
patients were treated with ivabradine. All other variables, including
efficacy endpoints, were balanced between the therapy and con-
trol groups. The median pre-implant NT-proBNP was 882 pg/ml
Figure 1 Consort diagram for neural cardiac therapy for heart failure.
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(inter-quartile range, IQR: 488–1926) and 879 (IQR: 370–1843) for
control and therapy patients, respectively. The median pre-implant
CRP levels were 2.6 mg/mL (IQR: 1.9–12.0) and 2.1 mg/mL (IQR:
1.0–4.7) for control and therapy patients, respectively.
Therapy
The mean stimulation amplitude for the therapy patients at the end of
the 3rd titration was 1.24+0.74 mA, and 1.42+0.80 mA after the
3-month follow-up visit. The self-reported threshold for activating
the laryngeal fibres at the 3rd titration visit was 0.99+0.67 mA,
and 1.17+0.74 mA at the 3-month follow-up visit. During the full
6-month randomization period, there were 10 patients that were
defined as having lost therapy due to magnet reset of the device
(six patients), failure to adequately re-charge the stimulator (two
patients), system explant due to infection (one patient), and elective
deactivation of the device (one patient).
Blinding
Table2 showsthe results of ablinding assessment thatwas performed
at the 6-month follow-up visit. The blinding index ranged from 0.31
in the inactive therapy group to 0.70 in the active therapy arm.
Efficacy endpoints
Table 3 shows a summary of the primary and secondary endpoint
outcomes. Analysis of the primary endpoint of LVESD revealed
comparable changes from baseline to 6 months in the therapy and
control groups. Other echocardiographic endpoints (LVEDD,
LVESV, left ventricular end diastolic volume, and LVEF) and the add-
itional endpoints of exercise capacity (peak VO2) and NT-proBNP
likewise showed comparable changes in the two groups. Analysis of
MLHFQ and SF-36 demonstrated statistically significant improve-
ment with VNS treatment when compared with control. Figure 3
displays the NYHA results, showing that 62% of patients in the
therapy group improved their functional class at least one point
compared with only 45% of control patients (P ¼ 0.032). Additional
analyses, performed using pure intention to treat (imputed missing
data), failed to show significance in echocardiography related
measures. An as-treated analysis, excluding patients defined as
having lost therapy (described above) did not alter the results of
the primary or secondary endpoint outcomes. Finally, indexing
the echocardiography analysis to body surface area did not impact
the results.
Figure 2 (A) Investigational bipolar helical vagal cuff. (B) Preci-
sion(TM) Pulse Generator and implanted lead.
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Table 1 Baseline patient characteristics at enrolment







Gender: male, n (%) 56 (89) 26 (81) 0.31
Age 59.8+12.2 59.3+10.1 0.87
Body mass index 28.6+5.9 31.2+5.1 0.02
NYHA II/III 7/51 7/22 0.22
ICD/CRT-D/No device 51/5/7 22/4/6 0.68
Resting heart rate (bpm) 68.2+13.2 71.3+12.9 0.24
Blood pressure (mmHg)
Systolic 118+17 115+16 0.39




44 (70) 20 (63) 0.47
Hypertension, n (%) 29 (46) 21 (66) 0.07
Renal disease n (%) 12 (19) 9 (28) 0.31
Heart failure
hospitalization past
6 months, n (%)
8 (13) 4 (13) 0.98
Previous myocardial
infarction, n (%)
42 (67) 19 (59) 0.48
Non-insulin dependent
diabetes, n (%)
14 (22) 9 (28) 0.53
Sleep apnoea, n (%) 9 (14) 3 (9) 0.50
Cardiovascular medications




51 (81) 24 (75) 0.50
Angiotensin receptor
blocker, n (%)




43 (68) 23 (72) 0.72
Loop diuretics, n (%) 54 (86) 32 (100) 0.02
Statin, n (%) 50 (79) 19 (59) 0.04
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As shown in Table 4, analysis of the 24-h Holter data did not reveal
statistically significant differences in the changes from baseline to 6
months for minimum, maximum, or mean HR. Time domain mea-
sures of heart rate variability showed that SDANN was statistically
increased in the active treatment group when compared with the
control group, but not for RMSSD, SDNN, and the traditional
frequency domain parameters.
Safety
Table 5 shows adverse events for the control and therapy groups.
One patient died pre-randomization from 4 days post-operatively
from a pulmonary embolism. There were three patient deaths that
occurred between randomization and 6 months; two patients rando-
mized to the control group died from heart failure complications 40
and 124 days after VNS implant, and one patient randomized to
therapy died 127 days after VNS implant from worsening heart
failure.
An overall infection rate of 7.4% (7 infections) associated with the
implanted system occurred in the entire cohort of 95 patients; three
infections resulted in explant of the VNS system (two control, one
therapy). Four infections were managed with antibiotics. One
patient needed a pulse generator pocket revision because of
problems recharging the device, and another patient underwent
lead revision due to inappropriate lead movement. There were no
significant differences in the occurrence of ICD shock delivery and/
or anti-tachycardia pacing between the two groups (VNS-therapy
9.5%, control 6.5%; P ¼ 0.71). All ICD shocks and anti-tachycardia
pacing were adjudicated and determined not to be associated with
interference from the investigational system.
Discussion
NECTAR-HF is the first randomized controlled trial to investigate
a prescribed right-sided VNS protocol in an HF population. The
study failed to demonstrate an improvement in LV remodelling
parameters, LV function, or circulating biomarkers following 6
months of chronic VNS at the prescribed stimulation settings.
NECTAR-HF did however demonstrate significant improvements
in the subjective endpoints of NYHA functional class and heart
failure related quality-of-life measures, although these findings
should be interpreted with caution given the imperfect patient-
level blinding (Table 2). The safety profile for this application of
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Table 3 Changes in primary and secondary efficacy endpoints from baseline to 6 months for therapy and control patients
Endpoint N Therapy Control P-valuea
Baseline 6-month Baseline 6-month
LVESD (cm) 86 4.9+0.9 4.9+0.8 5.2+0.7 5.1+0.8 0.60
LVEDD (cm) 86 5.9+0.7 5.8+0.7 6.0+0.6 6.0+0.7 0.84
LVEDV (ml) 86 218.3+67.1 207.4+68.5 235.4+46.7 221.3+49.3 0.36
LVESV (ml) 86 154.7+58.5 142.5+57.1 164.0+39.2 152.1+43.8 0.86
LVEF (%) 86 30.5+6.0 32.7+6.4 30.8+4.2 32.1+5.6 0.27
Peak VO2 (ml/kg/min) 83 15.6+3.9 15.8+4.4 15.2+3.3 14.7+3.6 0.26
MLHFQ score 87 44.4+22.2 35.8+20.8 42.8+25.1 41.8+24.3 0.049
SF-36 physical 85 36.3+7.6 41.2+7.9 37.7+7.9 38.4+8.4 0.02
SF-36 mental 85 41.2+7.9 43.8+10.8 40.7+10.9 41.1+10.7 0.24
NT-proBNP 84 879 (370–1843) 930 (409–1938) 882 (488–1926) 839 (302–1847) 0.41
LVESD, left ventricular end systolic diameter; LVEDD, left ventricular end diastolic diameter; LVEDV, left ventricular end diastolic volume; LVESV, left ventricular end systolic volume;
LVEF, left ventricular ejection fraction; MLHFQ, Minnesota Living with Heart Failure Questionnaire.
Data presented as mean+ SD for all values except NT-proBNP which is median (inter-quartile range). MLWHFQ intergroup difference, 95% confidence interval ¼ 27.7 (214.3,
20.03); SF-36 intergroup difference (95% confidence interval) ¼ 3.7 (0.7, 26.7).
aComparing the therapy and control deltas from baseline to 6 months.
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Table 2 At the 6-month follow-up visit, patients were asked what to which group they believed they were randomized
6 months
Randomization group Patients’ response to blinding Blinding Index (95% CI)
On Off Did not know
Off 7 (24.1%) 16 (55.2%) 6 (20.7%) 0.31 (0.08, 0.54)
On 44 (77.2%) 4 (7.0%) 9 (15.8%) 0.70 (0.48, 0.92)
Data are presented as N (%). A blinding index of 0 means blinding was perfect, and score of 1 would be completely un-blinded.
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VNS appeared acceptable, with an overall infection rate compar-
able with that in patients implanted with a VNS system for the
treatment of epilepsy.10 The small volume to implants per
centre and the level of device implant experience likely contribu-
ted to an infection rate that was higher than is seen for other
cardiac devices.
Figure 3 New York Heart Association class change from baseline to Month 6 (P ¼ 0.032).
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Table 4 Results of the 24-h Holter analysis
Therapy (N 5 55) Control (N 5 28) P-value
Baseline 6 months D therapy Baseline 6 months D control
RMSSD (ms+ SD) 78.8+41.8 97.0+40.2 18.2+50.9 94.5+31.5 89.9+37.0 24.7 + 45.5 0.26
SDNN (ms+ SD) 146+48.3 129.7+52.1 216.3 + 60.3 146.3+47.2 132.1+41.3 214.2 + 60.9 0.83
SDANN (ms+ SD) 29.1+2.1 29.4+2.3 0.3+2.0 29.6+2.5 28.8+2.2 20.8 + 2.1 0.03
Mean HR (bpm+ SD) 70.1+10.4 70.7+10.0 0.5+8.2 69.2+9.7 73.0+10.7 3.8+8.7 0.10
Minimum HR (bpm+ SD) 54.6+9.2 53.2+8.0 21.5 + 7.6 53.4+8.6 54.6+10.0 1.3+6.8 0.14
Maximum HR (bpm+ SD) 102.4+15.7 107.4+19.2 4.9+19.3 101.0+15.9 109.0+17.9 7.9+17.2 0.56
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Table 5 Summary of the serious adverse events and serious adverse device effects for the control and therapy patients
Therapy (N 5 63) Control (N 5 32)
Events Patients % Events Patients %
Death and/or HF hospitalization 11 7 11.1 11 5 15.6
Death 1 1 1.6 2 2 6.3
HF hospitalization 10 7 11.1 9 5 15.6
Cardiovascular–Non-HF 9 7 11.1 7 5 15.6
Non-cardiovascular 8 8 12.7 12 11 34.4
Pulmonary 0 0 0.0 3 3 9.4
Genitourinary 1 1 1.6 2 2 6.3
Other Non-cardiovascular 7 7 11.1 7 7 21.9
Investigational system related* 9 9 14.3 4 4 12.5
Data are reported for events ≥5%.
*Includes post-surgical infections of the lead and pulse generator, pulse generator failure leading to loss of therapy, and right recurrent laryngeal nerve injury.
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The lack of cardiac remodelling benefit was an unexpected finding
given the results from pre-clinical experiments3,4,11,12 and the initial
open-label pilot study.6 Several potential factors may have played a
role in the apparent lack of translation from pre-clinical experiments
to the randomized sham-controlled feasibility clinical study.
In the open-label pilot study of 32 systolic heart failure patients,6
the results suggested a beneficial effect on LV remodelling, LV func-
tion, 6-min hall walk, and NYHA class. The most important distinc-
tion between the two studies is the inclusion of a sham-treated
control group in NECTAR-HF, which was absent in the previous
pilot study. Although difficult to implement in device trials,13 the
inclusion of a concurrent control group is of paramount importance,
as recently underlined by the results of the Simplicity III trial.14 In the
current study, patients receiving therapy reported significant
improvements in heart failure related quality-of-life and NYHA func-
tional class. This may be in part due to a placebo effect. Indeed,
despite efforts to keep investigators and patients blinded to the deliv-
ered therapy, more patients in the therapy group correctly guessed
their randomization assignment (Table 2). Titrating to the highest
comfortable amplitude likely resulted in some patients detecting
the sensation caused by chronic VNS. Control patients experienced
these sensations only during titration. Thus, an assessment of appro-
priate blinding is important in randomized controlled device trials
where proper blinding is challenging and often under-reported.15
Another potential reason for the observed lack of objective
benefit in NECTAR-HF may be related to an incomplete understand-
ing of appropriate dosing of VNS in humans. There are numerous
stimulation parameters that can be deployed which impact the
‘dose’ of VNS a patient may receive: frequency, amplitude, duty
cycle, timing to the cardiac cycle, and efferent/afferent nerve activa-
tion.16 The two parameters that are likely to be of most relevance
for the activation of vagus nerves are the amplitude and the stimula-
tion frequency. It is acknowledged from the large experience with
VNS for epilepsy17 and by the experience of De Ferrari et al.6 that
in most patients the titration of the stimulation to higher amplitudes
is limited by side effects, which may impact the dose delivered.
The most appropriate technique of increasing ‘physiologic’ vagus
nerve activation is still a matter of debate. In the present study,
therapy patients experienced side effects (e.g. neck pain, coughing),
which limited programming to low stimulation amplitudes. Since it
appears that stimulation amplitude is inversely correlated with the
stimulation frequency, the delivery of VNS at 20 Hz in NECTAR-HF
may have reduced the maximum achievable current (mA). NECTAR-
HF reached relatively low current (average 1.4+0.8 mA) compared
with a prior study investigating very low frequency (1–2 pulses per
cardiac cycle, i.e. 1–3 Hz) that reached much higher current (4.1+
1.2 mA).6 By using a lower frequency, it may be possible to attain
higher amplitudes of stimulation, which in turn allows the recruitment
of a greater number of vagal fibres.18,19 However, it should be noted
that pre-clinical studies in an established animal model of heart
failure20 showed robust efficacy using NECTAR-HF stimulation para-
meters, and provided a strong rational for the use of a low amplitude,
20 Hz stimulation.12 Results were comparable with those using lower
frequencyandhigheramplitudes.4Thepreferential activationofefferent
vs. afferent vagal fibres has also been proposed as an important thera-
peutic parameter. Efferent stimulation may be beneficial because of
the direct innervation of the heart. However, afferent vagal stimulation
may also contribute to the beneficial effects, leading to sympathetic
withdrawal.21 The present study employed a helical bipolar electrode
known to activate the nerve bi-directionally (i.e. both afferent and effer-
ent vagal fibres).18 In contrast, the study by De Ferrari et al.6 employed
anasymmetric bipolarmulti-contact cuff electrode designed for prefer-
ential, but not exclusive, activation of vagal efferent fibres. Thus, stimu-
lation characteristics may have contributed to the lack of significant
benefit in NECTAR-HF, but on-going clinical trials are investigating al-
ternativeapplicationparameterswhichmayprovideadditional informa-
tion. Autonomic Neural Regulation Therapy to Enhance Myocardial
Function in Heart Failure is investigating 10 Hz VNS,22 and Increase of
Vagal Tone in Chronic Heart Failure23 is investigating an asymmetric
bipolar multi-contact cuff electrode delivering 1–2 pulses per cardiac
cycle. Results of these studies may further provide insight into the
‘dosing’ dependencies of VNS for human heart failure.
Cardiac resynchronization is one of the few implantable devices for
the treatment of chronic heart failure, and has been shown to induce a
robust beneficial cardiac remodelling effect in the first 6 months and
beyond.24 However, it may not be appropriate to compare CRT
with VNS given the likely mechanistic differences, and thus the
6 month randomized period of this trial may have been too short to
detect changes in cardiac remodelling. Remodelling will be further
assessed at the scheduled 12- and 18-month follow-up visits.
However, the lack of a concurrent control group after the 6-month
randomization period will limit the interpretation of the findings.
Inappropriate patient selection may have also contributed to the
neutral findings. The relatively low levels of NT-proBNP, the lack
of cardiac remodelling progression, and the low levels of inflamma-
tory markers suggest that patients were well managed and in a stabi-
lized phase of their HF trajectory. The selection of patients with
direct markers of autonomic imbalance could enhance the potential
to respond to vagal stimulation. The regulation of systemic inflamma-
tion by the vagus nerve has been demonstrated in a series of acute
experimental studies25– 29 and although the mechanism by which
this occurs is not well understood30 the selection of patients with
markers of systemic inflammation may also be considered. Thus,
compared with the pre-clinical models with active remodelling and
evidence of inflammation, the relatively controlled heart failure pro-
gression in the NECTAR-HF patients may have limited the ability to
demonstrate the benefit of VNS.
The importance of heart rate variability has been demonstrated pre-
viously.31 Results of the Holter data in the present study suggest that
VNS had no effect in decreasing the mean, minimum or maximum
HR, but showed a modest effect in modulating HR variability through
an improvement in SDANN. There was also a non-significant improve-
ment in RMSSD. Whether the magnitude of change observed in this
study has a biological significance or not is unclear.
Although robust pre-clinical data showed the benefit of VNS, the
NECTAR-HF trial failed to demonstrate a successful clinical transla-
tion of VNS therapy to the primary endpoint. There were statistically
significant improvements seen in the quality-of-life measures, and
there were no significant safety concerns. The specified stimulation
protocol of VNS used in this randomized sham-controlled clinical
trial was shown to be ineffective for the treatment of heart failure.
Additional clinical research still needs to be performed to determine
if alternative translation methods can become an effective heart
failure therapy.
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Completely percutaneous repair of a failing surgical mitral valve repair
Luiz Carlos Bergoli1,2, Pieter Vriesendorp1, Ramón Rodrı́guez-Olivares1, and Nicolas M. Van Mieghem1*
1Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Room Bd 171, ‘s Gravendijkwal, CE Rotterdam 230 3015, the Netherlands; and 2Hospital de
Clı́nicas de Porto Alegre, Porto Alegre, RS, Brazil
* Corresponding author. Tel: +31 107035260, Fax: +31 104369154, Email: n.vanmieghem@erasmusmc.nl
A 70-year-old female patient with hypertrophic car-
diomyopathy was admitted 18 months after surgical
septal myectomy, venous bypass of the left circum-
flex artery, and mitral valve repair using an autolo-
gous pericardial patch extension of the anterior
mitral leaflet. Echocardiogram revealed severe
mitral insufficiency with a central regurgitation
based on malcoaptation of the mitral leaflets and
an additional leak due to a perforation in the anter-
ior leaflet patch (Panel A). The heart team agreed
upon Mitraclip implantation and plug closure of
the patch perforation.
Panel B demonstrates the mitraclip opening in the
left ventricle before leaflet grasping. The mitral
double orifice after Mitraclip implantation as seen
by three-dimensional by transoesophageal echo-
cardiography (TOE) is shown in Panel C. Panels D
and E display the residual leak through the patch
(red arrow) after mitraclip (arrowhead) implant-
ation. The patch perforation is crossed by a
6-French multipurpose diagnostic catheter (Panel F—TOE, Panel G Fluoroscopy, note mitraclip (*) in situ). A 8 × 6 mm AMPLATZERTM
Duct Occluder (St Jude Medical, St Paul, MN, USA) is deployed in the patch perforation with initially mild residual patch leakage (Panel H—
TOE). Transthoracic echocardiography 4 days laterconfirms mild central mitral regurgitationwith no residual patch leakage (Panel I). Panel J
(TTE) and K (fluoroscopy) illustrate the mitraclip (*) and duct occluder within the patch (arrow) in situ.
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